Close
Smartlab Europe
Inizio Ignite

Drug Research

Johnson & Johnson opens California Innovation Center

Johnson & Johnson (J&J) Innovation has opened the new California Innovation Center to build early stage collaborations with emerging companies in science and technology and advance healthcare. The new centre has the flexibility to adapt...

Second Genome signs microbiome drug discovery deal with Janssen

Second Genome has signed a microbiome drug discovery deal with Janssen Biotech to advance novel drug targets mediated by the bacterial ecosystem living within the human gut to treat ulcerative colitis. Under the collaboration, Janssen...

USPTO issues notice of allowance for GW Pharmaceuticals Sativex formulation spray device

The USPTO has issued a notice of allowance for GW Pharmaceuticals' patent application regarding Sativex formulation spray device. The patent alleges a metered valve pump spray device comprising a liquid cannabis extract, in propylene...

Nuvo Research announces launch of Pliaglis in Europe

Specialty pharmaceutical company Nuvo Research has announced the launch of Pliaglis (lidocaine and tetracaine) cream 7%/7% by Galderma in Europe. Galderma has worldwide marketing rights for Nuvo's Pliaglis, a topical local anesthetic cream indicated...

UK, India sign deal to support R&D, innovation projects

The Technology Strategy Board (TSB) in the UK and the Indian government's Department of Science and Technology have signed 'Programme of Co-operation' deal to support joint, collaborative research and development (R&D) and innovation projects in key areas, including...

ImmBio gets Biomedical Catalyst support to develop pneumococcal vaccine PnuBioVax

Immunobiology (ImmBio), a UK-based biopharmaceutical company, has bagged £0.2m in funding from the UK government-backed Biomedical Catalyst (BBC) for the pre-clinical development of pneumococcal vaccine PnuBioVax. The pharma company had also received £1m from...

Merck, Luminex collaborate to develop companion diagnostic device

Merck, referred to as MSD outside the US and Canada, and Luminex have signed a deal to develop a companion diagnostic device to support patient selection for the clinical development program of investigational drug MK-8931 to treat Alzheimer's...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »